Sheraz R Markar1, Hugh Mackenzie2, Sameh Mikhail2,3, Muntzer Mughal4, Shaun R Preston5, Nick D Maynard6, Omar Faiz2,7, George B Hanna2. 1. Division of Surgery, Department of Surgery and Cancer, Imperial College London, 10th Floor QEQM Building, St. Mary's Hospital, South Wharf Road, London, W21NY, UK. s.markar@imperial.ac.uk. 2. Division of Surgery, Department of Surgery and Cancer, Imperial College London, 10th Floor QEQM Building, St. Mary's Hospital, South Wharf Road, London, W21NY, UK. 3. Department of General Surgery, Cairo University, Giza, Egypt. 4. Department of Surgery, University College London Hospital, London, UK. 5. The Oesophago-Gastric Unit, Department of Surgery, Royal Surrey County Hospital, Guildford, UK. 6. Oxford Oesophagogastric Center, Churchill Hospital, Oxford, UK. 7. St. Mark's Hospital and Academic Institute, Harrow, UK.
Abstract
BACKGROUND: The objectives of this national study were to examine the short-term safety and long-term survival benefit associated with surgical resection of hepatic metastases from gastric cancer. METHODS: Patients from the Hospital Episode Statistics database were classified by disease and treatment approach. Gastric cancer: 1. Without liver metastases treated by gastrectomy (GG). 2. With liver metastases treated by gastrectomy and hepatectomy (GGH). 3. With liver metastases treated by gastrectomy without hepatectomy (GGNH). 4. With liver metastases treated with no surgery (GNS). Propensity score matching and multivariable analyses were used to compensate for differences in some baseline characteristics. RESULTS: During the study period, 87,482 were patients diagnosed with gastric cancer, of whom 13,841 underwent partial or total gastrectomy. Of those who underwent gastrectomy, 336 had a diagnosis of liver metastases and 78 of these had a hepatectomy. Propensity-matched analysis showed no significant differences in 30- or 90-day mortality between the GGH and GG groups. The GGH group had significantly improved 1-year mortality (35.9 % vs. 50.0 %, p = 0.049) and 5-year mortality (61.5 % vs. 75.7 %, p = 0.031) compared to the GGNH group, and compared to the GNS group, the GCH group had 1-year mortality (35.9 % vs. 84.6 %, p < 0.001) and 5-year mortality (61.5 % vs. 90.8 %, p < 0.001). CONCLUSIONS: This study showed that hepatectomy for synchronous gastric cancer hepatic metastases may carry survival benefits in selected patients. The data presented should not be a rationale to change current clinical practice but rather a stimulus to prospectively study the role of surgery in a selected group of patients who are currently treated with palliative chemotherapy.
BACKGROUND: The objectives of this national study were to examine the short-term safety and long-term survival benefit associated with surgical resection of hepatic metastases from gastric cancer. METHODS:Patients from the Hospital Episode Statistics database were classified by disease and treatment approach. Gastric cancer: 1. Without liver metastases treated by gastrectomy (GG). 2. With liver metastases treated by gastrectomy and hepatectomy (GGH). 3. With liver metastases treated by gastrectomy without hepatectomy (GGNH). 4. With liver metastases treated with no surgery (GNS). Propensity score matching and multivariable analyses were used to compensate for differences in some baseline characteristics. RESULTS: During the study period, 87,482 were patients diagnosed with gastric cancer, of whom 13,841 underwent partial or total gastrectomy. Of those who underwent gastrectomy, 336 had a diagnosis of liver metastases and 78 of these had a hepatectomy. Propensity-matched analysis showed no significant differences in 30- or 90-day mortality between the GGH and GG groups. The GGH group had significantly improved 1-year mortality (35.9 % vs. 50.0 %, p = 0.049) and 5-year mortality (61.5 % vs. 75.7 %, p = 0.031) compared to the GGNH group, and compared to the GNS group, the GCH group had 1-year mortality (35.9 % vs. 84.6 %, p < 0.001) and 5-year mortality (61.5 % vs. 90.8 %, p < 0.001). CONCLUSIONS: This study showed that hepatectomy for synchronous gastric cancer hepatic metastases may carry survival benefits in selected patients. The data presented should not be a rationale to change current clinical practice but rather a stimulus to prospectively study the role of surgery in a selected group of patients who are currently treated with palliative chemotherapy.
Authors: William H Allum; Jane M Blazeby; S Michael Griffin; David Cunningham; Janusz A Jankowski; Rachel Wong Journal: Gut Date: 2011-06-24 Impact factor: 23.059
Authors: G A M Tiberio; A Coniglio; A Marchet; D Marrelli; S Giacopuzzi; L Baiocchi; F Roviello; G de Manzoni; D Nitti; S M Giulini Journal: Eur J Surg Oncol Date: 2009-01-25 Impact factor: 4.424
Authors: Sheraz R Markar; Sameh Mikhail; George Malietzis; Thanos Athanasiou; Christophe Mariette; Mitsuru Sasako; George B Hanna Journal: Ann Surg Date: 2016-06 Impact factor: 12.969
Authors: A Thelen; S Jonas; C Benckert; E Lopez-Hänninen; U Neumann; B Rudolph; G Schumacher; P Neuhaus Journal: Eur J Surg Oncol Date: 2008-03-10 Impact factor: 4.424